ASJYD ameliorates CUMS-induced behavioral deficits, reduces hypothalamic-pituitary-adrenal axis hyperactivity, is associated with increased phosphorylation of AKT and mTOR, and protects against hippocampal neuronal damage.
Li et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: